Lifestyle Drugs Outlook to 2005

Published by: Business Insights

Published: Feb. 1, 1999 - 130 Pages

Table of Contents

• Defining lifestyle drugs
  
• Epidemiology
  
• Market analysis
  
• Lifestyle drugs in R&D
  
• Lifestyle drugs in the 21 st century

Chapter 1 Defining lifestyle drugs

• Summary
  
• Introduction
  
  • The myth
    
  • The media
  
  
  
• A definition
  
  • Social characteristics
    
  • Disease characteristics
    
  • Product characteristics
    
  • Summary
  
  
  
• Marketing
  
  • Corporate control
    
  • The downside to mass media interest
  
  
  
• Pricing
  
• Reimbursement
  
  • Treatment vs. Enhancement
    
  • The lifestyle share
    
  • Prescription control
    
  • Setting precedents: Viagra
  
  
  
• Drivers and limiters of lifestyle drug success

Chapter 2 Epidemiology

• Summary
  
• Methodology
  
• Drivers of incidence of lifestyle conditions
  
  • Diagnosed prevalence
    
  • Absolute prevalence
  
  
  
• Prevalence of lifestyle conditions
  
  • Depression
    
  • Erectile dysfunction
    
  • Obesity
    
  • Alopecia
  
  
  
• Cost of disease
  
  • Obesity
  
  
  
• Cost of treatment
  
  • Viagra
    
  • Xenical
    
  • Seroxat

Chapter 3 Market analysis

• Summary
  
• The lifestyle drug market
  
• Alopecia
  
  • Suitability to lifestyle drugs
    
  • Merck
    
  • Pharmacia & Upjohn
    
  • Market dynamics
  
  
  
• Depression
  
  • Suitability to lifestyle drugs
    
  • Eli Lilly
    
  • Pfizer
    
  • SmithKline Beecham
    
  • Market dynamics
  
  
  
• Erectile dysfunction
  
  • Suitability to lifestyle drugs
    
  • Astra
    
  • Pharmacia & Upjohn
    
  • Pfizer
    
  • Market dynamics
  
  
  
• Obesity
  
  • Suitability to lifestyle drugs
    
  • American Home Products
    
  • Knoll
    
  • Roche
  
  
  
• Oral contraception
  
  • Suitability to lifestyle drugs
    
  • American Home Products
    
  • Akzo Nobel
    
  • Johnson & Johnson
    
  • Schering AG
  
  
  
• Skin ageing
  
  • Suitability to lifestyle drugs
    
  • Johnson & Johnson
    
  • Allergan
    
  • Market dynamics
  
  
  
• Other lifestyle contenders
  
  • Zyban (smoking cessation)
    
  • Celebra (arthritis)
    
  • Aricept (cognitive)
    
  • Lipitor (lipid-lowering)
  
  
  
• Lifestyle drug market dynamics

Chapter 4 Lifestyle drugs in R&D

• Summary
  
• Alopecia
  
  • MK386
    
  • GI 198745
  
  
  
• Depression
  
• Erectile dysfunction
  
  • Cashing in on Viagra
  
  
  
• Obesity
  
  • ZD2079
    
  • Leptin
    
  • SR 58611
  
  
  
• Oral contraception
  
  • Drospiredone

Chapter 5 Lifestyle drugs in the 21st
century

• Summary
  
• Future opportunities for growth
  
  • Market size and potential
    
  • Market growth by therapeutic area
    
  • Market growth by company
  
  
  
• The downside: the fen-phen problem
  
  • The fen-phen calamity
    
  • Anticipation and hype: dexfenfluramine reaching the US market
    
  • The drug withdrawals
    
  • Impact on other drugs and future opportunities
  
  
  
• New lifestyle drugs
  
  • The international outlook
    
  • Methods of discovery
  
  
  
• DTC marketing
  
  • The suitability of lifestyle drugs to DTC marketing
    
  • Brand awareness
    
  • DTC marketing spend
    
  • DTC advertising in Europe

Chapter 6 Appendix

• Primary research methodology
  
• Index

List of Figures

• Figure 1.1: The sales power of lifestyle drugs
  
• Figure 1.2: Characteristics of lifestyle drugs
  
• Figure 1.3: Assessing the medical importance of lifestyle drugs
  
• Figure 1.4: Drivers and inhibitors of lifestyle drug sales
  
• Figure 2.5: The ageing population
  
• Figure 2.6: US population aged 65 and over, 1990-2050
  
• Figure 2.7: Global prevalence of depression
  
• Figure 2.8: US trends in prevalent population of depression by age
  
• Figure 2.9: Patient potential for erectile dysfunction
  
• Figure 2.10: Trends in prevalence of obesity, 1998-2005
  
• Figure 3.11: Rogaine and Propecia sales, 1998
  
• Figure 3.12: Sales growth of the three leading antidepressants, 1994-98
  
• Figure 3.13: Sales of Viagra and Caverject, 1998
  
• Figure 3.14: Sales of Botox and Renova
  
• Figure 4.15: Competitive positioning of products currently in development compared to existing
  classes of antidepressants
  
• Figure 5.16: Growth in the key lifestyle drug sectors
  
• Figure 5.17: Growth in the antidepressant market
  
• Figure 5.18: Growth in the obesity market
  
• Figure 5.19: Growth in the erectile dysfunction market
  
• Figure 5.20: Growth in the skin ageing market
  
• Figure 5.21: Growth in the oral contraception market
  
• Figure 5.22: Growth in company lifestyle drug portfolios
  
• Figure 5.23: Annual DTC expenditure in the US: 1989-97

List of Tables

• Table 1.1: Viagra prices, 1998
  
• Table 1.2: Possible misuse of lifestyle drugs
  
• Table 1.3: Viagra reimbursement in Europe, 1998
  
• Table 2.4: Global prevalence of depression by population 1990-2005 (000s)
  
• Table 2.5: US prevalence of depression by population 1990 - 2005
  
• Table 2.6: Global prevalence of depression 1990 - 2005 (000s)
  
• Table 2.7: The potential market for erectile dysfunction treatments
  
• Table 2.8: Prevalent obese populations and forecasts in selected markets, 1998
  
• Table 3.9: Sales of lifestyle drugs, 1997-8
  
• Table 3.10: Propecia sales, 1998
  
• Table 3.11: Rogaine sales, 1994-98
  
• Table 3.12: Prozac sales, 1994-98
  
• Table 3.13: Zoloft sales, 1994-1998
  
• Table 3.14: Paxil sales, 1994-98
  
• Table 3.15: Caverject sales, 1994-98
  
• Table 3.16: Viagra sales, 1998
  
• Table 3.17: Pondimin and Redux sales, 1993-97
  
• Table 3.18: Renova sales, 1995-98
  
• Table 3.19: Botox sales, 1994-98
  
• Table 4.20: Key alopecia drugs in development, 1998
  
• Table 4.21: Key antidepression compounds in development, 1998
  
• Table 4.22: Key erectile dysfunction compounds in development, 1998
  
• Table 4.23: Key anti-obesity compounds in development, 1998
  
• Table 4.24: Key contraceptive compounds in development, 1998
  
• Table 4.25: Key skin ageing products in development
  
• Table 5.26: DTC expenditure in the US, 1987

Abstract

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 300,000 market research reports, company profiles and country profiles from over 700 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.